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Abstract
A correlation between components of the insulin-like growth factor (IGF) system and endometrial cancer risk has been shown
in recent studies. The antitumor action of vorinostat, a histone deacetylase inhibitor, involves changes in the expression of
specific genes via acetylation of histones and transcription factors. The aim of this study was to establish whether vorinostat
can modify the expression of specific genes related to the IGF-I receptor (IGF-IR) signaling pathway and revert the transformed
phenotype. Human endometrioid (Type I, Ishikawa) and uterine serous papillary (Type II, USPC-2) endometrial cancer cell lines
were treated with vorinostat in the presence or absence of IGF-I. Vorinostat increased IGF-IR phosphorylation, produced
acetylation of histone H3, up-regulated pTEN and p21 expression, and reduced p53 and cyclin D1 levels in Ishikawa cells.
Vorinostat up-regulatedIGF-IR andp21 expression, produced acetylation of histone H3, and down-regulatedtheexpressionof
total AKT, pTEN and cyclin D1 in USPC-2 cells. Of interest, IGF-IR activation was associated with a major elevation in IGF-IR
promoter activity. In addition, vorinostat treatment induced apoptosis in both cell lines and abolished the anti-apoptotic
activity of IGF-I both in the absence or presence of a humanized monoclonal IGF-IR antibody, MK-0646. Finally, vorinostat
treatment led to a significant decrease in proliferation and colony forming capability in both cell lines. In summary, our studies
demonstrate that vorinostat exhibits a potent apoptotic and anti-proliferative effect in both Type I and II endometrial cancer
cells, thus suggesting that endometrial cancer may be therapeutically targeted by vorinostat.
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Introduction
Endometrial cancer is the most common gynecologic cancer
in Western countries. The incidence of the disease has been
increasing in recent years as a result of the growing obesity
epidemics and, therefore, endometrial cancer constitutes a major
public health issue. Endometrial cancers are classified into two
major groups, Type I and Type II, with Type I being the most
frequent (more than 80% of cases) [1,2]. Type I tumors are usually
estrogen-dependent, low-grade neoplasms, with an endometrioid,
well-differentiated morphology, and are generally associated with
a relatively good prognosis. Type II tumors appear at an advanced
age, are not associated with exposure to estrogens, display a less
differentiated phenotype, and have a worse prognosis. Uterine
serous carcinoma (USC) constitutes the predominant histological
class among Type II tumors [3,4]. USC represents 10% of all
endometrial carcinomas, is diagnosed at an advanced stage, and
accounts for 50% of all relapses of the endometrial cancers, with a
5-year survival rate of 55%. A number of different genetic
abnormalities have been detected in Type I endometrial cancers,
including microsatellite instability and mutations of the pTEN, k-
RAS, and ß-catenin genes. Type II tumors, on the other hand,
often exhibit p53 mutations and loss of heterozygosity on several
chromosomes [5].
The insulin-like growth factor (IGF) system plays an important
role in the biology of endometrial cancer [6]. Correlations between
the expression of components of the IGF system and endometrial
cancer risk and development have been reported [7,8]. Most of the
biological actions of IGF-I and IGF-II are mediated by the IGF-I
receptor (IGF-IR), a membrane-bound heterotetramer with potent
anti-apoptotic and cell-survival activities [9–11]. The IGF-IR
emerged in recent years as a promising molecular target in
oncology and a number of approaches are currently being
employed to target the receptor for therapeutic purposes [8,12].
Vorinostat is a novel histone deacetylase inhibitor (HDAC)
(Zolinza, suberoylanilide hydroxamic acid or SAHA; Merck
Research Laboratories), representing a new class of potential
antitumor agents. Vorinostat induces growth arrest, differentia-
tion, and/or apoptosis in a variety of transformed cells, including
prostate, leukemia, breast, and colon cancers [13], and has under-
gone initial evaluation in Phase I and II clinical trials [14,15]. The
mechanism/s underlying the anti-tumor action of vorinostat is not
yet clear but may involve changes in the expression of specific genes
via acetylation of histones and transcription factors as well as non-
transcriptional effects such as inhibition of mitosis. The aim of this
studywastoestablish whetherthe mechanismofactionofvorinostat
involves changes in the expression or activity of specific genes
related to the IGF-IR signaling pathway. In addition, we aimed at
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24468characterizing the anti-carcinogenic and pro-apoptotic actions of
vorinostat in both Type I and II endometrial cancer cells, including
its potential ability to render the cells more sensitive to
chemotherapy.
Materials and Methods
Cell lines and treatments
The human endometrioid Ishikawa cell line (Type I) was
obtained from Dr. Y. Sharoni, Ben Gurion University, Beer-
Sheba, Israel. Uterine serous papillary (USPC-1 and USPC-2;
Type II) endometrial cancer cell lines were kindly provided by Dr.
A. Santin, Yale University School of Medicine, New Haven, CT,
USA. Ishikawa cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco BRLH, Paisley, Scotland) and USPC
cells were grown in RPMI-1640 medium (Biological Industries
Ltd., Kibbutz Beit-Haemek, Israel). Both media were supplement-
ed with 10% fetal bovine serum (FBS), 2 mM glutamine, and
50 mg/ml gentamicin sulfate. All reagents were purchased from
Biological Industries Ltd. In addition, 5.6 mg/l amphotericin B
was added (Sigma-Aldrich, St. Louis, MO, USA). Cells were
incubated at 37uC in a humidified atmosphere containing 5%
CO2. Vorinostat was obtained from Merck, Sharp & Dohme Israel
(Petach Tikva, Israel), kept as a stock solution (100 mM) in DMSO
and stored at 220uC. In all of the experiments, cells were serum-
starved for 24 h, after which they were treated with 5 mM
vorinostat, in the absence or presence of IGF-I (50 ng/ml)
(PeproTech Ltd, Rocky Hill, NJ, USA). For cell growth assays,
doses of 3 mMo r5mM vorinostat were used, either in the absence
or presence of 5 mMo r1 0mM cisplatin (Sigma-Aldrich). In some
experiments, cells were treated with 5 mM vorinostat for 24 h,
separately and in combination with 10 mg/ml MK-0646, a
humanized monoclonal IGF-IR antibody (Merck & Co Inc.,
Whitehouse Station, NJ, USA) during the last 5 h of the
incubation period, or in the presence or absence of IGF-I
(50 ng/ml) for 24 h, or during the last 10 min of the incubation
period, as indicated.
Western immunoblots
Cells were lysed in a buffer containing protease inhibitors
(#9803, Cell Signaling Technology Beverly, MA, USA). Protein
content was determined using the Bradford reagent (Bio-Rad Ltd.,
Hercules, CA, USA) and bovine serum albumin (BSA) as a
standard. Samples were electrophoresed through 15%, 12%, 10%,
7.5% or 5% SDS-PAGE gels, followed by blotting of the proteins
onto nitrocellulose membranes. After blocking with either skim
milk and/or 3% BSA, the blots were incubated overnight with the
antibodies listed below, washed, and incubated with the
appropriate horseradish peroxidase (HRP)-conjugated secondary
antibody. Antibodies against phospho-IGF-IR (3024), IGF-IR
b-subunit (3027), insulin receptor [(IR); 3025], phospho-AKT
(9271), AKT (9272), phospho-ERK1/2 (9106), poly ADP ribose
polymerase [(PARP); 9542], caspase 3 (9661), phospho-Ampk
(2531), Ampk (2532), phospho-mTor (5536), mTor (2983), and
PI3K p85 (4292) were obtained from Cell Signaling Technology.
Antibodies against ERK1 (K-23), p21 (C-19), Bcl2 (C-2), p53
(mixture of DO-1 and Pab 1801), pTEN (A2B1), cyclin D1
(H295), and caspase 9 (H-83) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). An antibody against actin
(Clone C4) was purchased from ICN Biomedicals, Inc. (Aurora,
OH USA), anti-acetyl histone H3 was from Upstate/Millipore
(Billerica, MA, USA), and anti-caspase 8 (M032-3) was obtained
from Medical & Biological Laboratories Co. Ltd. (Wobum, MA,
USA). The secondary antibodies were HRP-conjugated goat
anti-rabbit IgG (1:50,000) and donkey anti-mouse IgG (1:25,000;
Jackson ImmunoResearch Laboratories, West Grove, PA,
USA). Proteins were detected using the SuperSignal West
PicoChemiluminescent Substrate (Pierce, Rockford, IL, USA).
The expression of actin was measured as a loading control of total
proteins.
Transfections and luciferase assays
For transient cotransfection experiments an IGF-IR promoter
luciferase reporter construct including 476 bp of the 59-flanking
and 640 bp of the 59-untranslated regions of the IGF-IR gene
[p(2476/+640) luciferase (LUC)] was employed [16,17]. Ishikawa
and USPC-2 cells were seeded in six-well plates the day before
transfection and cotransfected with 1 mg of the IGF-IR promoter
reporter along with 0.2 mg of a ß-galactosidase plasmid (pCMVß,
Clontech, Palo Alto, CA, USA), using the Jet-PEI transfection
reagent (Polyplus, Illkirch, France). Vorinostat was added to the
medium after 24 h. Cells were harvested 48 h after transfection
and luciferase and ß-galactosidase activities were measured as
described [16]. Promoter activities were expressed as luciferase
values normalized for ß-galactosidase activity.
Proliferation assays
Cells were seeded onto 24-well plates (1.8610
4 Ishikawa cells/
well and 3.6610
4 USPC-2 cells/well). After 24 h, the cells were
treated with vorinostat in combination with cisplatin for 24 h,
48 h, or 72 h in triplicate wells. Cell viability was assessed using a
standard Thiazolyl Blue Tetrazolium Bromide (MTT) method
[18]. The color developed was quantitated by measuring
absorbance at a wavelength of 530 nm and reference wavelength
of 630 nm on a Microplate Reader (SpectraMax 190, Molecular
Devices, Sunnyvale, CA, USA). Cell viability was expressed as
percentage of optical density values obtained upon treatment
relative to control.
Cell cycle analysis
Cells were seeded in 6-well plates (1610
6 cells/well) for 24 h.
Cells were then serum-starved for an additional 24 h and
incubated in the presence or absence of vorinostat for 72 h. After
incubation cells were washed with phosphate buffered saline,
trypsinized, permeabilized with Triton X-100 (4%) and stained
with propidium iodide (50 mg/ml). Stained cells were analyzed
using a FacsCalibur system (Cytek Development Inc, Fremont,
CA, USA).
Soft agar colony formation assays
To determine colony formation in soft agar, cells were added to
the top-layer agar (Difco Noble agar, Difco Laboratories, Detroit,
MI, USA), in triplicate [19]. Briefly, 2 ml of 0.6% soft agar/
complete culture medium at 42uC were added to Ishikawa
(2.5610
4 Ishikawa cells/well) and USPC-1 (1.2610
4 USPC-1
cells/well) cells, gently mixed by pipetting up and down, and put
onto 6-well plates with a 0.6% soft agar underlay. The agar was
allowed to harden for 10 min and then incubated at 37uC.
Vorinostat was added 24 h after platting, and the cells were
incubated for another 22 days. The medium overlay was changed
twice a week. Colonies were photographed with 406 and 2006
objectives and the number of colonies larger than 3 mm diameter
was counted using an inverted microscope.
Wound-healing assays
A wound-healing assay was performed using a previously
described protocol [20]. Briefly, Ishikawa and USPC-2 cells were
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the cell monolayer using a sterile micropipette tip. Then, cells were
cultured at 37uC in starvation medium, in the presence or absence
of IGF-I in combination with vorinostat. At time 0, the scratched
monolayer cultures were photographed using an inverted
microscope (ECLIPSE Ti, Nikon Corp, USA). Cell movement
was assessed 48 h and 72 h after wounding from photographs
taken under the microscope with a 106objective.
Results
Effect of vorinostat on the IGF-I signaling pathway
To evaluate the potential regulation of the expression and
activation of IGF-IR and downstream signaling mediators by
vorinostat in endometrial cancer, Ishikawa and USPC-2 cells were
treated with vorinostat for 24 h, in the presence or absence of
IGF-I during the last 10 min of the incubation period (Figure 1).
As expected, IGF-I stimulated phosphorylation of IGF-IR in both
cell lines. Vorinostat enhanced the IGF-I-stimulated IGF-IR
phosphorylation in Ishikawa cells. In contrast, pretreatment with
vorinostat slightly reduced the IGF-I-induced phosphorylation of
IGF-IR in USPC-2 cells. Vorinostat alone induced a moderate
decrease in IGF-IR phosphorylation compared with untreated
cells. Vorinostat markedly up-regulated the level of p21 in both
cell types. The induction of p21 is commonly used as a marker of
HDAC inhibition [21]. Moreover, vorinostat up-regulated the
expression of IGF-IR, insulin receptor (IR), and AKT but did not
alter the expression of ERK1/2 in USPC-2 cells. In addition,
vorinostat led to a decrease in AKT phosphorylation in USPC-2
cells. As shown in Figure 1, the levels of IR and AKT were similar
in vorinostat-treated and untreated Ishikawa cells.
Effect of vorinostat on the induction of apoptosis and
acetyl-histone H3
To examine the potential effect of vorinostat on apoptosis, cells
were serum-starved for 24 h and then treated with vorinostat in
the absence or presence of IGF-I (50 ng/ml) for 24 h. Apoptosis
was assessed by cleaved PARP and caspase 3 measurements using
Western blots. The cleavage of the ,116-kDa PARP molecule
into an ,85-kDa band is considered a typical hallmark of early
apoptosis [22]. Results obtained showed that, after 24 h, IGF-I
treatment prevented the appearance of the ,85-kDa band in
Ishikawa cells (Figure 2A). Under our experimental conditions,
however, IGF-I, by itself, had a reduced anti-apoptotic effect in
USPC-2 cells. Vorinostat induced apoptosis in both cell lines and
abolished the anti-apoptotic activity of IGF-I. The extent of the
Figure 1. Effect of vorinostat on IGF-I-mediated signal transduction. Ishikawa and USPC-2 cells were treated for 24 h with vorinostat (or left
untreated) and/or IGF-I during the last 10 min of the incubation period. Whole-cell lysates (100 mg) were resolved on SDS-PAGE and immunoblotted
with antibodies against pIGF-IR, TIGF-IR, pAKT, TAKT, pERK1/2, TERK1/2, p21, and actin. The figure shows the result of a typical experiment, repeated
three times with similar results. IGF-IR phosphorylation in USPC-2 cells was significantly lower than in Ishikawa cells and was detected by Western blot
analysis only after longer exposure times of blots to X-ray film. Therefore, this experiment does not allow comparison between both cell lines in terms
of levels of expression or phosphorylation.
doi:10.1371/journal.pone.0024468.g001
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,85-kDa PARP band, was more pronounced in Ishikawa than in
USPC-2 cells. To address the potentially different sensitivity to
vorinostat in both cell lines, the role of caspase 3 in regulating
vorinostat-induced apoptosis was investigated. Caspase 3 has been
shown to be a key component of the apoptotic machinery. Caspase
3 is activated in apoptotic cells and cleaves several cellular
proteins, including PARP. Western blot analysis revealed that
Ishikawa and USPC-2 cells express very low levels of endogenous
caspase 3 (Figure 2B). Vorinostat led to a modest increase in the
cleavage of caspase 3 in USPC-2 and to a very large increase in the
cleaved form of caspase 3 in Ishikawa cells. To further explore the
molecular mechanisms that control apoptosis in USPC-2 cells,
Bcl2 and caspase 8 immunoblotting analyses were carried out in
vorinostat-treated cells. Results obtained showed that basal Bcl2
levels were very low. Furthermore, IGF-I, both in the absence or
presence of vorinostat, up-regulated, and vorinostat down-
regulated Bcl2 levels (Figure 2C). Vorinostat-treated cells exhibited
markedly diminished full-length caspase 8 levels. On the other
hand, IGF-I treatment (both in the presence or absence of
vorinostat) had a minor effect on the levels of the full-length and a
cleaved form of caspase 8 with a MW of ,25-kDa (Figure 2D).
Taken together, the data indicate that vorinostat induced caspase
3 activation and PARP cleavage in Ishikawa cells. In addition,
vorinostat led to a large decrease in the expression of Bcl2 and full-
length caspase 8, and increased both full-length and cleaved PARP
in USPC-2 cells. Finally, analysis of the acetylation level of histone
H3 by Western blots showed that vorinostat hyperacetylated
histone H3 in both cell lines (Figure 2B).
Effect of vorinostat on specific transcription factors
involved in IGF-IR gene regulation
Studies have shown that vorinostat modulates the transcription
of multiple genes in cancer cells [23,24]. No studies, however, have
thus far addressed the effect of vorinostat on transcription factors
and transcriptional mechanisms involved in regulation of IGF-IR
gene expression. We chose to examine the effect of vorinostat on
tumor suppressors p53 and pTEN expression. The rationale for
this choice is the fact that both p53 and pTEN were shown to
downregulate IGF-IR expression [25,26]. For this purpose, cells
were treated with vorinostat in the presence or absence of IGF-I,
and p53 and pTEN expression was analyzed by Western blots.
The data demonstrate that vorinostat increased pTEN expression
and reduced p53 levels in Ishikawa cells (Figure 3). Furthermore,
vorinostat down-regulated the expression of both p53 and pTEN
in USPC-2 cells. Similar results were obtained when Ishikawa and
USPC-2 cells were treated with vorinostat followed by IGF-I
stimulation. As expected, vorinostat hyperacetylated histone H3 in
Figure 2. Effect of vorinostat on apoptosis and acetyl-histone H3. Western blot analysis of PARP (A) on Ishikawa and USPC-2 cells and
caspase 3 (B), Bcl2 (C) and caspase 8 (D) on USPC-2 cells. Cells were treated with vorinostat for 24 h in the absence or presence of IGF-I. After
incubation, cell lysates were prepared and electrophoresed (100 mg for Bcl2 or 70 mg for caspases 3 and 8). Caspase 3 expression in USPC-2 cells was
detected after a long exposure time of blots to X-ray film. Results are representative of three independent experiments.
doi:10.1371/journal.pone.0024468.g002
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bottom panel).
Effect of vorinostat on IGF-IR promoter activity
To determine whether the increase in IGF-IR gene expression
in vorinostat-treated Ishikawa and USPC-2 cells is mediated at the
level of transcription, cells were transiently transfected with a
luciferase reporter gene under the control of the IGF-IR promoter.
Twenty-four hours after transfection, vorinostat (5 mM, or vehicle)
was added to the medium and incubated for an additional 24 h.
Cells were then collected and promoter activity was measured.
The results indicate that vorinostat induced a significant increase
in IGF-IR promoter activity in both cell lines. Specifically,
vorinostat enhanced IGF-IR-promoter activity by 398615% in
Ishikawa and by 1446629% in USPC-2 cells versus control
untreated cells [100% (Figure 4)].
Figure 4. Regulation of IGF-IR promoter activity by vorinostat in endometrial cancer cells. Ishikawa and USPC-2 cells were transiently
transfected with an IGF-IR promoter-luciferase reporter plasmid, p(2476/+640)LUC, which contains most of the proximal region of the IGF-IR
promoter, and a ß-galactosidase vector. Promoter activity is expressed as luciferase values normalized for ß-galactosidase. A value of 100% was given
to the promoter activity in the absence of vorinostat. Results are mean 6 S.E.M. (three independent experiments); p*,0.01 versus untreated cells.
doi:10.1371/journal.pone.0024468.g004
Figure 3. Effect of vorinostat on p53 and pTEN expression. Ishikawa and USPC-2 cells were treated for 24 h with vorinostat (or left untreated)
and/or IGF-I. Whole-cell lysates (100 mg) were resolved on SDS-PAGE and immunoblotted with antibodies against p53, pTEN, acetyl-histone H3 and
actin. Western blot analysis revealed that basal p53 levels were much lower in USPC-2 than in Ishikawa cells and were detected after long exposure
times. Results represent a typical experiment out of three independent experiments.
doi:10.1371/journal.pone.0024468.g003
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To assess the anti-proliferative effect of vorinostat, Ishikawa and
USPC-2 cells were cultured in 10% serum-containing media with
vorinostat and/or cisplatin for 72 h. The proliferation rate was
determined by MTT assays. Results obtained showed that
vorinostat or cisplatin alone inhibited the proliferation rate in
both cell lines compared with untreated cells. Thus, in Ishikawa
cells, 5 mM vorinostat decreased proliferation rate by 25%, 76%,
and 73% and 10 mM cisplatin decreased proliferation rate by
8.9%, 42%, and 55%, at 24 h, 48 h and 72 h, respectively
(Figure 5A). Vorinostat in combination with cisplatin had no
additive effect in comparison to vorinostat alone in Ishikawa cells.
Marked decreases in proliferation were seen in USPC-2 cells with
low doses (3 mM) of vorinostat (28%, 47%, and 51% reductions, at
24 h, 48 h, and 72 h, respectively) and cisplatin (5 mM) (5%, 25%,
and 60% reductions, at 24 h, 48 h, and 72 h respectively)
(Figure 5B). The combination of vorinostat with cisplatin led to
significantly greater growth inhibition rates than chemotherapy
alone in USPC-2 cells at 48 h and 72 h (60% and 76% reductions,
respectively). These data indicate that combination treatment in
these cells resulted in a synergistic decrease in proliferation
compared to single agent treatment.
Effect of vorinostat on cell cycle
To examine the effect of vorinostat on cell cycle progression,
cells were incubated with vorinostat (or left untreated), stained
with propidium iodide, and analyzed by flow cytometry. In
Ishikawa cells, vorinostat reduced the proportion of cells at the
Go/G1 phase from 60.1461.1% to 56.9661.9% and at the S
phase from 16.3162.5% to 3.8360.98%, and increased the
proportion of cells at the G2 phase from 13.9561.5% to
37.3362.2% (Table 1). Similarly, in USPC-2 cells vorinostat
Figure 5. Effect of vorinostat on endometrial cancer cells proliferation. Cells were plated in 24-well plates at a density of 2610
4 cells/well for
Ishikawa (A) and 3610
4 cells/well for USPC-2 (B). The bars represent the mean 6 S.E.M. of three independent experiments, performed each in
triplicate; * p,0.05 versus untreated cells.
doi:10.1371/journal.pone.0024468.g005
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49.3662.0% and at S phase from 4.4662.5% to 0.7160.09%,
and increased the proportion of cells at G2 from 24.4461.5% to
48.961.7%.
Effect of vorinostat on the mTor and Ampk pathway
To evaluate the effect of vorinostat on the mammalian Target of
Rapamycin (mTor) pathway, cells were treated with vorinostat in
the presence or absence of IGF-I, and mTor and PI3K levels were
measured by Western blots. Results obtained showed no changes
in phosphorylation and total mTor levels after treatment with
IGF-I in the absence or presence of vorinostat in Ishikawa cells
(Figure 6). On the other hand, vorinostat, in the presence or
absence of IGF-I, stimulated mTor phosphorylation in USPC-2
cells. No changes in total mTor levels and a mild increase in PI3K
levels were seen in both cells. Next, the effect of vorinostat on
Ampk was assessed. Vorinostat, in the presence or absence of IGF-
I, activated Ampk in Ishikawa and reduced Ampk phosphorylation
in USPC-2 cells. Cell cycle regulatory proteins p21 and cyclin D1
were also analyzed by Western blots following exposure to
vorinostat. As shown above, vorinostat markedly up-regulated
Table 1. Effect of vorinostat on the cell cycle in endometrial
cancer cells.
Cells Control Vorinostat
Ishikawa
G0/G1 60.14561.1 56.96561.9*
S 16.3162.5 3.8360.98*
G2 13.9561.5 37.33562.2*
USPC-2
G0/G1 70.79563.6 49.36562.0*
S 4.46562.5 0.7160.09*
G2 24.44561.5 48.961.7*
Ishikawa and USPC-2 cells were seeded in duplicate dishes, serum-starved for
24 h, and treated with vorinostat (or left untreated, controls) for 72 h. Cell cycle
distribution was assessed by FACS analysis. The values in the Table denote
mean 6 SEM;
*p#0.05 versus controls.
doi:10.1371/journal.pone.0024468.t001
Figure 6. Effect of vorinostat on the mTor and Ampk signaling pathway in endometrial cancer cells. Ishikawa and USPC-2 cells were
treated with vorinostat and/or IGF-I, and cell lysates (100 mg) were prepared after 24 h. Western blot analysis was performed with antibodies against
pmTor, T-mTor, p-Ampk, T-Ampk, p21, cyclin D1, PI3K and actin. The figure shows the results of a typical experiment, repeated three times with
similar results.
doi:10.1371/journal.pone.0024468.g006
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D1 (Figure 6) in both cell lines. This data suggest that vorinostat
may cause growth arrest at the G1-S stage of the cell cycle by
regulating p21 and cyclin D1 levels.
Vorinostat inhibits colony formation in endometrial
cancer cell lines
To corroborate the growth inhibitory effect of vorinostat, a soft-
agar colony formation assay was used. Vorinostat (3 mM) led to a
significant inhibition in the number of colonies in Ishikawa and
USPC-1 cells (Figures 7A, B and C) compared with untreated cells
(4464 versus 11761.3 colonies in Ishikawa cells, and 1361.3 versus
4362.7 colonies in USPC-1 cells).
Vorinostat inhibits cell migration in endometrial cancer
cell lines
To test the effect of vorinostat on cell migration, scratch wound
migration assays were performed as described in Materials and
Methods. Cells were incubated in serum-free media containing
IGF-I (50 ng/ml), vorinostat (5 mM), or both, for 48 h or 72 h.
Data obtained showed that both untreated and IGF-I-treated
Ishikawa and USPC-2 cells migrated at similar rates over 72 h
(Figure 8 A and B). Vorinostat, both in the presence or absence of
IGF-I, inhibited migration of both cell lines.
Does the pro-apoptotic effect of vorinostat require IGF-IR
action?
Finally, we investigated whether the pro-apoptotic effect of
vorinostat requires IGF-IR action. For this purpose, cells were
treated with vorinostat for 24 h, separately and in combination
with MK-0646, a blocking monoclonal anti-IGF-IR antibody, in
the presence or absence of IGF-I, after which apoptosis was
assessed by caspase 9 measurements. As shown in Figure 9A, MK-
0646, alone and in combination with IGF-I and/or vorinostat,
induced a significant decrease in total IGF-IR levels in both cells
lines. Furthermore, Western blot analysis revealed that vorinostat
abolished the anti-apoptotic activity of IGF-I both in the absence
or presence of MK-0646, thus suggesting that the pro-
apoptotic action of vorinostat does not require IGF-IR action
(Figure 9 B).
Figure 7. Colony formation in soft agar. A total of 1.5610
4 Ishikawa cells and 1.2610
4 USPC-1 cells were seeded on 6-well plates in soft agar. The
formed colonies were photographed at a magnification of 406and 2006(A) and colonies with diameters greater than 3 mm were counted (B) at day
22. The bars represent the mean 6 S.E.M. of three independent wells; * p,0.05 versus untreated cells.
doi:10.1371/journal.pone.0024468.g007
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Uterine serous carcinoma is a very aggressive cancer for which
there are no effective therapeutic protocols. There is, therefore, an
urgent need to identify new therapeutic regimens that will prolong
survival of USC patients and that will transform response to
treatment into cure. In this study we demonstrate that vorinostat, a
histone deacetylase inhibitor, markedly induces the accumulation
of acetylated histone H3, leading to transcriptional modulation of
specific gene programs, including genes involved in IGF-IR and
downstream mediators regulation. Our results demonstrate that
vorinostat induced apoptosis, growth arrest, and inhibition of
migration and colony formation in Type I and II endometrial
cancer cell lines. In addition, we demonstrate that inhibition of
HDAC modulates IGF-IR expression in Ishikawa and USPC-2
cells lines. The Ishikawa cell line was derived from a well
differentiated adenocarcinoma and is a validated model for Type I
endometrial cancer. Type I cancers express the estrogen and
progesterone receptors [27], exhibit microsatellite instability, and
include mutations in the ras proto-oncogene, p53 [28] and pTEN
tumor suppressor genes, resulting in deregulated PI3K signaling
and activation of AKT. In addition, they secrete IL-6, TGF-alpha
and IGF-II, but not IGF-I [29]. By contrast, Type II tumors show
mutations in p53 [30], but almost never have microsatellite
Figure 8. Effect of vorinostat on wound healing assays in endometrial cancer cells. Wounds were made on monolayers of Ishikawa (A) and
USPC-2 (B) cells grown to 100% confluence. Untreated (control) cells or cells treated with vorinostat and/or IGF-I were photographed just after scratch
(time 0), and after 48 h and 72 h. Results presented here are representative of triplicate independent samples of each cell line.
doi:10.1371/journal.pone.0024468.g008
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HER-2/neu oncogene, and secrete IGF’s, IGFBP and IL-6.
PTEN was shown to downregulate IGF-II and IGF-IR
expression in hepatoma and prostate cancer cells, respectively,
suggesting that the anti-proliferative effects of pTEN are, at least in
part, mediated through the regulation of expression of components
of the IGF system [26,31]. Vorinostat was shown to down-regulate
autocrine IGF-I production and expression, and the IGF-IR in
multiple myeloma [32]. A number of studies have shown a
correlation between components of the IGF system and endome-
trial cancer risk. The IGF system has autocrine and paracrine
functions in the regulation of endometrial proliferation and
differentiation [33]. Results of migration assays suggest that both
cell lines secrete growth factors and/or cytokines responsible for
their proliferative effects. In particular, a highly mitogenic effect
was seen in USPC-2 cells. Vorinostat, both in the presence or
absence of IGF-I, inhibited migration of both cell lines. Western
blot analyses showed that vorinostat robustly increased the IGF-I-
stimulated IGF-IR phosphorylation in Ishikawa cells. Further-
more, alone or in combination with IGF-I, vorinostat up-regulated
total IGF-IR levels. A potential explanation for the increase in
IGF-IR phosphorylation in Ishikawa cells is the reported
vorinostat-induced down-regulation of endogenous IGF-II. This
reduction may shift the competition between secreted IGF-II and
exogenous IGF-I, leading to an increase in IGF-I binding with
ensuing enhanced activation. In addition, the expression of a
constitutively-active AKT in Ishikawa cells (as a result of loss of
pTEN) significantly increased the total IGF-IR expression. This
effect might be mediated at the level of transcription, as shown by
the large increase in IGF-IR promoter activity.
A number of epigenetic drugs have already been approved for
the treatment of hematological malignancies [34]. These drugs
include demethylating agents and HDAC inhibitors such as
trichostatin A. Previous studies showed that treatment of mice
fibroblasts with trichostatin A induced partial relaxation of
genomic imprinting as well as decreased DNA methylation of
both IGF-IIR sense and antisense promoters. Hence, increases in
histone acetylation can lead to decreased DNA methylation,
thereby modulating the regulation of the imprinted expression of
IGF-IIR sense and antisense transcripts. Interestingly, Risinger et
al reported that promoter hypermethylation is common in Type I,
but not Type II, endometrial tumors [35]. HDAC inhibitors can
also induce TNF-related apoptosis-inducing ligand (TRAIL) [36],
suggesting the activation of the death receptor pathway without
the requirement of exogenous TRAIL, leading to activation of
caspase 8 [37]. Our data suggest that vorinostat may modulate
apoptotic cell death by both the extrinsic and intrinsic pathways in
USPC-2 cells because it changed the activation of caspase 8, the
expression of Bcl2, and further contributed to caspase 3 activation,
following activation of caspase 9. Vorinostat-induced apoptosis in
Figure 9. Effect of vorinostat and/or antibody MK-0646 on apoptosis and IGF-IR protein levels. Ishikawa and USPC-2 cells were treated
with vorinostat for 24 h, separately and in combination with MK-0646, in the presence or absence of IGF-I. Whole-cell lysates (70 mg for caspase 9 and
100 mg for total IGF-IR and p21 proteins detection) were resolved by SDS-PAGE and immunoblotted with antibodies against T-IGF-IR and p21 (A) and
caspase 9 (B). The figure shows the results of a typical experiment, repeated twice with similar results.
doi:10.1371/journal.pone.0024468.g009
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activation of caspase 3 was accompanied by PARP cleavage into
an 85-kDa fragment in both cells lines. Moreover, our data
showed that the pro-apoptotic action of vorinostat is not correlated
with IGF-IR levels.
Lu et al reported that a high level of mTor activity is a
consistent feature of endometrial carcinomas. Activation of mTor
occurred in tumors that had lost pTEN, resulting in deregulated
PI3K signaling and activation of AKT. While pTEN alterations
are well known in endometrial cancer, signaling defects involving
the downstream effector mTor, or other tumor suppressors that
regulate mTor signaling, including TSC2 and LKB1, are less
documented [38]. Constitutive mTor expression was observed in
Ishikawa cells including an inactive pTEN. In addition, vorinostat-
induced activation of mTor in USPC-2 cells might be mediated
via the PI3K/AKT and p53/Ampk signaling pathways. Alterna-
tively, activation of mTor expression might be induced by p53-
independent mechanisms. No data, however, is available regard-
ing the p53 status in USPC-2 cells. Previous investigations have
provided evidence to support the view that the presence of an
intact p53 is essential for an efficient HDAC inhibitor-induced
apoptotic response [39]. This dependence appears to vary with the
agent used and may be due to differences in potency.
Furthermore, acetylation of p53 occurs following HDAC inhibitor
treatment and may increase its activity and reduce targeting of p53
for degradation [40,41]. However, others have shown that HDAC
inhibitors induce apoptosis via p53-independent mechanisms [41].
More experiments are required to define the role of p53 in the
vorinostat-mediated apoptosis of USPC-2 cells.
Studies have shown that HDAC inhibitors are relatively non-
toxic to normal cells or tissues, exhibiting selective cytotoxicity
against a wide range of cancer cells. A number of HDAC
inhibitors are currently being investigated in clinical trials against
hematological and solid tumors, both as single agents and in
combination with other cytotoxic therapies [42]. MTT analysis
revealed a significant anti-proliferative activity of vorinostat in
both cell lines assayed and a synergistic effect of combined
treatment of vorinostat with cisplatin in USPC-2 cells. In addition,
cell cycle analyses have shown that vorinostat is able to arrest cell
cycle progression in endometrial cancer cells. Recent studies have
demonstrated that the HDAC inhibitor-mediated induction of p21
was the result of increased H3 and H4 acetylation associated with
the p21 gene promoter [43,44]. These results are in line with
preclinical and clinical data showing that H3 and H4 acetylation
are important biomarkers for vorinostat action [18]. P21 is
member of the family of endogenous cyclin-dependent kinase
inhibitors that negatively regulate cell cycle progression and cyclin
D1, a positive regulator of cell cycle progression. Our data show
that vorinostat increased p21 expression and inhibited cyclin D1
expression in both cell types, with ensuing growth arrest. In
summary, our studies demonstrate that vorinostat exhibits a potent
apoptotic and anti-proliferative effect in both Type I and II
endometrial cancer cell lines, strongly suggesting that endometrial
cancer may be therapeutically targeted by vorinostat.
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